Skip to content
IMUTEX Ltd logo — A joint venture between SEEK Group and hVIVO, part of Open O...

IMUTEX Ltd

A joint venture between SEEK Group and hVIVO, part of Open Orphan plc, to accelerate the development of FLU-v & AGS-v

Founded 2016 2 employees Seed Total: $14.00M Biotechnology, Health Care

General Information

Company Name IMUTEX Ltd
Founded Year 2016
Employees 2
Industries Biotechnology, Health Care
Funding Stage Seed
Social

BounceWatch is an independent company data service, not affiliated with IMUTEX Ltd. To contact IMUTEX Ltd, visit imutex.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does IMUTEX Ltd compare?

A PDF of IMUTEX Ltd and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting IMUTEX Ltd soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About IMUTEX Ltd

IMUTEX Ltd is a joint venture between SEEK Group and hVIVO, part of Open Orphan plc, established in 2016. The company's mission is to expedite the development of a Broad-Spectrum ‘Universal’ Influenza Vaccine, FLU-v, and a Mosquito-Borne Diseases Vaccine, AGS-v. These vaccines are identified as key public health priorities by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) in the United States.

IMUTEX collaborates with the National Institute of Allergy and Infectious Diseases (NIAID) to hasten the development of both vaccines. The last investment of £14.00M was secured through a Seed Round from hVIVO and SEEK on 28 April 2016.

Operating in the Biotechnology and Health Care industries, IMUTEX aims to address pressing global health concerns while attracting notable investments from renowned entities in the field.

Business keywords: pharmaceuticals, vaccines, joint venture, public health, infectious diseases, vaccine development, partnership, medical research, CDC, NIH, NIAID, influenza

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round £14.00M 2
hVIVO, SEEK
28 Apr 2016

IMUTEX Ltd Alternatives & Competitors

View All Alternatives
IMUTEX Ltd vs
Novavax
Novavax United States

Powering innovation. Protecting health.

Post-IPO Equity
970 employees
Biotechnology, Health Care
IMUTEX Ltd vs

Vaccine R&D

Series A
7 employees
Biotechnology, Health Care
IMUTEX Ltd vs

Transforming vaccine efficacy in respiratory disease.

Grant
6 employees
Biotechnology, Health Care

FAQ About IMUTEX Ltd

A joint venture between SEEK Group and hVIVO, part of Open Orphan plc, to accelerate the development of FLU-v & AGS-v
IMUTEX Ltd was founded in 2016.
IMUTEX Ltd operates in Biotechnology and Health Care. Its work centres on pharmaceuticals, vaccines, joint venture and public health.
IMUTEX Ltd has approximately 2 employees.
IMUTEX Ltd has completed 1 funding round, raising a total of $14.00M. The latest funding stage is Seed.
Top alternatives and competitors to IMUTEX Ltd include Novavax, Inviragen, Inc., FLUGEN, INC., AdaptVac, Tulane National Primate Research Center. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
IMUTEX Ltd and Novavax are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for IMUTEX Ltd, https://bouncewatch.com/company/imutex-ltd, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout